RPA2 and ovarian carcinoma: To begin to explore this, we stained 9 HR-proficient primary ovarian cancer cells (POVs) (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI189511DS1) with an antibody against p-RPA2.